One To Watch

CellProthera

Company Overview

A French clinical-stage biotech advancing ProtheraCytes, an autologous CD34+ stem cell therapy for myocardial repair, toward a pivotal Phase III trial in heart failure patients across the US and Europe, with a separate route into Japan through Alfresa Holdings. CellProthera's core proposition is that harvesting and expanding a patient's own peripheral blood CD34+ progenitor cells, then delivering them directly into damaged myocardium, can regenerate cardiac tissue after acute myocardial infarction. The company describes itself as the first to have completed a successful proof-of-principle study with autologous CD34+ cells in this indication. With Phase I/IIb data peer-reviewed and published in JACC: Heart Failure, the programme now has a credible scientific foundation for its late-stage ambition.

Headquarters and Global Presence

CellProthera is headquartered in Mulhouse, France. Its clinical programme spans the UK, France, the US, and Europe for the planned Phase III study, with an emerging presence in Japan through two separate agreements with Japanese institutions. The company's manufacturing partnerships extend its operational footprint further across Europe.

Founding and History

CellProthera was founded in 2008 with a focus on stem cell therapies for cardiac repair. The company has progressed from early proof-of-concept work through Phase I and Phase IIb clinical studies, building the evidence base that now supports a pivotal trial application. In 2026 the company raised 8.3 million euros to fund its Phase III preparations, acquired delivery device rights from Celyad Oncology, and reinforced its board ahead of the next development stage.

Therapy Areas and Focus

CellProthera is focused on severe myocardial infarction and the heart failure that follows it, a condition where standard-of-care pharmacology and intervention stabilize but do not regenerate lost myocardial muscle. The clinical logic is that re-establishing viable tissue, rather than managing its absence, could meaningfully alter long-term outcomes for patients with severely compromised cardiac function. The company has also signaled an interest in stroke as a future indication for its cell manufacturing platform.

Technology Platforms and Modalities

The company's proprietary StemXpand platform expands human peripheral blood CD34+ progenitor cells ex vivo, converting them into the ProtheraCytes stem cell graft. Delivery is transendocardial, using a catheter technology now owned outright by CellProthera following its acquisition of the asset from Celyad Oncology in February 2026. The autologous approach is intended to sidestep immune rejection, and the CD34+ cell type carries both angiogenic and cardiomyogenic repair potential. Separately, a collaboration with Quintessence Biotech is introducing DACS flotation-based cell sorting to industrialize the manufacturing process at scale.

Key Pipeline and Programs

ProtheraCytes is CellProthera's lead and only disclosed clinical asset. It is an autologous CD34+ stem cell therapy delivered by transendocardial catheter, targeting myocardial repair in patients with severe heart failure following acute myocardial infarction. Phase I/IIb results, published in JACC: Heart Failure, demonstrated safety and feasibility in this population. The planned Phase III trial, expected to start in the first quarter of 2027, will run across sites in the United States and Europe; the FDA pre-IND meeting has been completed and trial design agreed with regulators. A parallel track in Japan is being advanced through the MOU signed with Alfresa Holdings in August 2026, with Phase III development in that market also under consideration. The StemXpand platform underpins future cell therapy applications in stroke, though no clinical programme has been disclosed for that indication.

Recent Developments

The pace of pre-Phase III activity in 2026 has been notable. On 12 February 2026, CellProthera acquired full rights to the transendocardial catheter from Celyad Oncology, securing control over its delivery system. On 28 April 2026, the company partnered with Quintessence Biotech to industrialize cell manufacturing using DACS technology. On 6 May 2026, Jerome Hirtzlin and Anne de la Fortelle were appointed to the Board of Directors. On 11 August 2026, CellProthera signed an MOU with Alfresa Holdings, Japan's number-one ethical pharmaceuticals wholesaler by net sales, covering Phase III development and future distribution of ProtheraCytes in Japan.

Key Personnel

Matthieu de Kalbermatten serves as Chief Executive Officer and has led the company's strategy for Phase III preparation, including manufacturing automation and geographic expansion. Jerome Hirtzlin and Anne de la Fortelle joined the Board of Directors in May 2026 to support the transition into late-stage clinical development.

Strategic Partnerships

CELLforCURE by SEQENS has been selected to manufacture the first GMP clinical batches of ProtheraCytes for the Phase III programme. Quintessence Biotech is collaborating on manufacturing industrialization using its DACS flotation-based cell sorting technology. In Japan, CellProthera has two separate agreements: a prior MOU with Shonan Kamakura General Hospital covering StemXpand use in a Japanese trial, and the August 2026 MOU with Alfresa Holdings covering Phase III development and wholesale distribution of ProtheraCytes across the country.

FAQ Section

Japan has a regulatory framework that can be relatively receptive to regenerative medicine products, and Alfresa Holdings brings distribution infrastructure as the country's top ethical pharmaceuticals wholesaler by net sales. The Shonan Kamakura General Hospital MOU for StemXpand preceded the Alfresa deal, suggesting a deliberate multi-year market-entry strategy rather than opportunistic deal-making. Securing a distribution partner before Phase III data exists is an unusual move, but reflects how commercially complex autologous cell therapy logistics will be at launch.

CD34+ cells are hematopoietic progenitor cells that carry both angiogenic and cardiomyogenic potential, meaning they can support new blood vessel formation and contribute to cardiac tissue regeneration when delivered to the injury site. Their presence in peripheral blood allows autologous harvest without bone marrow aspiration, which is a practical advantage in a post-infarction patient. The challenge historically has been expanding them to therapeutically relevant numbers, which is precisely what CellProthera's StemXpand platform is designed to solve.

Most cardiac cell therapy programmes have used bone marrow-derived cells or mesenchymal stem cells; CellProthera's focus on peripheral blood CD34+ cells, expanded via its proprietary StemXpand platform and delivered transendocardially, represents a more targeted cellular and mechanistic approach. Owning the catheter delivery system outright, following the acquisition from Celyad Oncology, gives CellProthera control over a component that has been a practical bottleneck for competitors. The autologous design removes allogeneic matching complexity, though it adds per-patient manufacturing demands that the Quintessence Biotech DACS partnership is designed to address.

The Phase I/IIb trial, conducted in the UK and France, demonstrated the safety and feasibility of ProtheraCytes in patients with severe heart failure following myocardial infarction; those results were peer-reviewed and published in JACC: Heart Failure, one of the leading cardiovascular journals. Publication in JACC: Heart Failure gives the data a level of independent scientific credibility that supports the FDA's willingness to align on a Phase III design. The study was not powered to demonstrate efficacy, so the pivotal trial starting in the first quarter of 2027 will be the first real test of whether the cardiac repair signal translates to meaningful clinical outcomes.

Heart failure following acute myocardial infarction is the primary and only active clinical indication. The company has indicated that its cell manufacturing platform, including the Quintessence Biotech DACS collaboration, is being developed with stroke applications in mind, but no clinical programme has been disclosed for that indication. The platform-expansion logic is coherent given that CD34+ cells have been studied in ischemic conditions beyond cardiac disease, but stroke remains a future ambition rather than an active pipeline asset.

CellProthera is in late-stage clinical preparation: Phase I/IIb is complete and published, the FDA pre-IND meeting is done with trial design agreed, and GMP manufacturing for Phase III batches has been contracted to CELLforCURE by SEQENS. The pivotal Phase III trial in the US and Europe is targeted to start in the first quarter of 2027. The 8.3 million euro financing round supports this transition, and the Alfresa Holdings MOU extends the development scope to Japan in parallel.

The company is at a critical juncture, with execution risk concentrated in the next 18 months.

Want to Update your Company's Profile?